Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
John E. Blundell,Graham Finlayson,Mads Axelsen,Anne Flint,Catherine Gibbons,Trine Kvist,Julie Hjerpsted +6 more
TLDR
The aim of this trial was to investigate the mechanism of action for body weight loss with semaglutide.Abstract:
Aim
The aim of this trial was to investigate the mechanism of action for body weight loss with semaglutide.
Materials and methods
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity. Ad libitum energy intake, ratings of appetite, thirst, nausea and well-being, control of eating, food preference, resting metabolic rate, body weight and body composition were assessed.
Results
After a standardised breakfast, semaglutide, compared with placebo, led to a lower ad libitum energy intake during lunch (−1255 kJ; P < .0001) and during the subsequent evening meal ( P = .0401) and snacks ( P = .0034), resulting in a 24% reduction in total energy intake across all ad libitum meals throughout the day (−3036 kJ; P < .0001). Fasting overall appetite suppression scores were improved with semaglutide vs placebo, while nausea ratings were similar. Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high-fat foods. Resting metabolic rate, adjusted for lean body mass, did not differ between treatments. Semaglutide led to a reduction from baseline in mean body weight of 5.0 kg, predominantly from body fat mass.
Conclusion
After 12 weeks of treatment, ad libitum energy intake was substantially lower with semaglutide vs placebo with a corresponding loss of body weight observed with semaglutide. In addition to reduced energy intake, likely mechanisms for semaglutide-induced weight loss included less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods.read more
Citations
More filters
Journal ArticleDOI
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Patrick M. O'Neil,Andreas L. Birkenfeld,Barbara McGowan,Ofri Mosenzon,Sue D. Pedersen,Sean Wharton,Charlotte Giwercman Carson,Cecilie Heerdegen Jepsen,Maria Kabisch,John P.H. Wilding +9 more
TL;DR: In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses.
Journal ArticleDOI
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
TL;DR: Given a similar, if not superior, effectiveness for HbA1c reduction with additional weight reduction and no intrinsic risk of hypoglycemic episodes, GLP-1RAs are recommended as the preferred first injectable glucose-lowering therapy for type 2 diabetes, even before insulin treatment.
Journal ArticleDOI
The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen,Jesper Lau +1 more
TL;DR: Rational design has led to the development of two long-acting GLP-1 analogs, liraglutide and semaglUTide, that have made a vast contribution to the management of T2D in terms of improvements in glycemic control, body weight, blood pressure, lipids, beta-cell function, and CV outcomes.
Journal ArticleDOI
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery,Casper Gravesen Salinas,Sarah J Paulsen,Jonas Ahnfelt-Rønne,Tomas Alanentalo,Arian F. Baquero,Stephen T. Buckley,Erzsébet Farkas,Csaba Fekete,Klaus Stensgaard Frederiksen,Hans Christian Cederberg Helms,Jacob Jeppesen,Linu M. John,Charles Pyke,Jane Nøhr,Tess Tsai Hsiu Lu,Joseph Polex-Wolf,Vincent Prevot,Kirsten Raun,Lotte Simonsen,Gao Sun,Anett Szilvásy-Szabó,Hanni Willenbrock,Anna Secher,Lotte Bjerre Knudsen +24 more
TL;DR: It is suggested semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.
Journal ArticleDOI
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi,Olivia M. Farr,Stergios A. Polyzos,Nikolaos Perakakis,Eric Nolen-Doerr,Aimilia Eirini Papathanasiou,Christos S. Mantzoros +6 more
TL;DR: Evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized and anti-obesity agents in the pipeline for potential future therapeutic use are presented.
References
More filters
Journal ArticleDOI
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P. Marso,Stephen C. Bain,A. Consoli,Freddy G. Eliaschewitz,Esteban Jódar,Lawrence A. Leiter,Ildiko Lingvay,Julio Rosenstock,Jochen Seufert,Mark Warren,Vincent Woo,O Hansen,Anders G. Holst,Jonas Pettersson,Tina Vilsbøll +14 more
TL;DR: In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, orNonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semag lutide.
Journal ArticleDOI
Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies.
TL;DR: VAS scores are reliable for appetite research and do not seem to be influenced by prior diet standardization, however, consideration should be given to the specific parameters being measured, their sensitivity and study power.
Journal ArticleDOI
The glucagon-like peptides.
TL;DR: The aim of this monograph is to clarify the role of Incretin in the development of Glucagon-Related Peptides in women and to provide a mechanistic basis for future research into their role in women's health.
Journal ArticleDOI
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer,Arne Astrup,Ken Fujioka,Frank L. Greenway,Alfredo Halpern,Michel Krempf,David C.W. Lau,Carel W. le Roux,Rafael Violante Ortiz,Christine B. Jensen,John P.H. Wilding +10 more
TL;DR: 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control in patients with type 2 diabetes and prediabetes.
Journal ArticleDOI
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
TL;DR: The results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.